Wealth Enhancement Trust Services’s Travere Therapeutics TVTX Stock Holding History

Wealth Enhancement Trust Services’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$625	Buy	+11	New	+$488	﹤0.01%	1207

Other funds holding TVTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealth Enhancement Trust Services's TVTX Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 11 shares worth $625. The stake represents ﹤0.01% of the portfolio and ranks #1207 among its holdings.

173 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Wealth Enhancement Trust Services held 11 shares of Travere Therapeutics worth $625 as of Q2 2026.
Travere Therapeutics was a new Wealth Enhancement Trust Services position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1207 holding.
173 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.